Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02151981 · ClinicalTrials.gov registry record · Phase 3
AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 3 study of Anticancer Treatment, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 421
- Enrollment target
- 20
- Study locations
NCT02151981 is a Phase 3 study of Anticancer Treatment that has completed, run by AstraZeneca. The registered enrollment target is 421 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT02151981, a Phase 3 study of Anticancer Treatment, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 421 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase III, Open Label, Randomized Study of Osimertinib versus Platinum-Based Doublet Chemotherapy for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and whose Tumours harbour a T790M mutation within the Epidermal Growth Factor Receptor Gene
Conditions Studied
Interventions
- DRUG Chemotherapy
- DRUG Cross-over to Osimertinib
Study Locations (20)
California
- Research Site - Anaheim
- Research Site - Orange
- Research Site - Santa Rosa
Florida
- Research Site - Gainesville
- Research Site - Orlando
- Research Site - Pembroke Pines
Washington
- Research Site - Lacey
- Research Site - Tacoma
Connecticut
- Research Site - Norwalk
Georgia
- Research Site - Atlanta
Illinois
- Research Site - Park Ridge
Indiana
- Research Site - Indianapolis
Louisiana
- Research Site - Marrero
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 421 participants |
| Start Date | 2014-08-04 |
| Est. Completion | 2023-12-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02151981
The ClinicalTrials.gov registry entry for NCT02151981 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 421 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Anticancer Treatment appearing as the primary indexed condition, and to 2 interventions - of which Chemotherapy is the first listed.
NCT02151981 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Florida, Washington.
Frequently Asked Questions
What is clinical trial NCT02151981 about?
NCT02151981 is a clinical study titled "AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer". A Phase III, Open Label, Randomized Study of Osimertinib versus Platinum-Based Doublet Chemotherapy for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and whose Tumo...
What is the current status of trial NCT02151981?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 421 participants. The study started on 2014-08-04. Estimated completion is 2023-12-15.
What conditions does trial NCT02151981 study?
This clinical trial studies the following conditions: Anticancer Treatment.
What interventions are being tested in trial NCT02151981?
The interventions under investigation include: Chemotherapy (DRUG), Cross-over to Osimertinib (DRUG).
Who is sponsoring clinical trial NCT02151981?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02151981 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.